DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $853,804 | -73.7% | 3,441 | -73.6% | 0.28% | -73.1% |
| Q2 2023 | $3,247,388 | -1.5% | 13,036 | -0.4% | 1.04% | -0.9% |
| Q1 2023 | $3,297,436 | +72659.0% | 13,083 | -23.4% | 1.05% | -30.4% |
| Q4 2022 | $4,532 | -99.9% | 17,073 | +2.4% | 1.51% | +0.9% |
| Q3 2022 | $4,306,000 | +20.7% | 16,672 | +18.4% | 1.50% | -44.8% |
| Q2 2022 | $3,569,000 | -11.7% | 14,077 | +2.1% | 2.71% | +3.5% |
| Q1 2022 | $4,044,000 | -7.7% | 13,786 | +3.6% | 2.62% | +1.5% |
| Q4 2021 | $4,380,000 | +13.3% | 13,313 | +4.9% | 2.58% | +5.6% |
| Q3 2021 | $3,865,000 | +16.2% | 12,697 | +3.1% | 2.45% | +12.8% |
| Q2 2021 | $3,327,000 | +20.6% | 12,316 | +0.5% | 2.17% | +6.2% |
| Q1 2021 | $2,759,000 | +5.1% | 12,257 | +3.7% | 2.04% | +30.9% |
| Q4 2020 | $2,625,000 | +8.2% | 11,815 | +4.9% | 1.56% | -19.0% |
| Q3 2020 | $2,426,000 | +29.7% | 11,266 | +6.5% | 1.93% | +22.3% |
| Q2 2020 | $1,871,000 | +10.8% | 10,581 | -13.2% | 1.58% | +3.2% |
| Q1 2020 | $1,688,000 | +3.6% | 12,193 | +14.8% | 1.53% | +28.0% |
| Q4 2019 | $1,629,000 | – | 10,617 | – | 1.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |